Related Experiment Video
Updated: Apr 15, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Clinical relevance of CYP3A5 genotype on maraviroc exposures
Manoli Vourvahis1, Lynn McFadyen2, Jayvant Heera2
1Pfizer Inc., Clinical Pharmacology, New York, New York (M.V.); Pfizer Inc., Pharmacometrics, Sandwich, United Kingdom (L.M.); Pfizer Inc., Clinical Development, Groton, Connecticut (J.H.); and ViiV Healthcare, London, United Kingdom (A.C.) manoli.vourvahis@pfizer.com.
No abstract available in PubMed .
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Therapeutic Drug Monitoring: Affecting Factors

